Kura Oncology Company Profile (NASDAQ:KURO)

About Kura Oncology (NASDAQ:KURO)

Kura Oncology logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KURO
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $174.1 million
  • Outstanding Shares: 14,508,000
Average Prices:
  • 50 Day Moving Avg: $12.00
  • 200 Day Moving Avg: $12.00
  • 52 Week Range: $12.00 - $12.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.80
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.08 per share
  • Price / Book: 2.94
Profitability:
  • EBIDTA: ($11,800,000.00)
 

Frequently Asked Questions for Kura Oncology (NASDAQ:KURO)

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURO."

Who are some of Kura Oncology's key competitors?

Who owns Kura Oncology stock?

Kura Oncology's stock is owned by a number of of retail and institutional investors. Top institutional investors include ECOR1 CAPITAL, LLC Total Shares: 3,766,852 (13.60%) and GREAT POINT PARTNERS LLC (5.92%). View Institutional Ownership Trends for Kura Oncology.

How do I buy Kura Oncology stock?

Shares of Kura Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kura Oncology's stock price today?

One share of Kura Oncology stock can currently be purchased for approximately $12.00.


MarketBeat Community Rating for Kura Oncology (NASDAQ KURO)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  49
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Kura Oncology (NASDAQ:KURO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Kura Oncology (NASDAQ:KURO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/30/2015Oppenheimer Holdings, Inc.Initiated CoverageOutperformN/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Kura Oncology (NASDAQ:KURO)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Kura Oncology (NASDAQ:KURO)
Current Year EPS Consensus Estimate: $-2.58 EPS
Next Year EPS Consensus Estimate: $-2.50 EPS

Dividends

Dividend History for Kura Oncology (NASDAQ:KURO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kura Oncology (NASDAQ:KURO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Kura Oncology (NASDAQ:KURO)
Latest Headlines for Kura Oncology (NASDAQ:KURO)
Source:
DateHeadline
247wallst.com logoKura Oncology Doubles on Mid-Stage Trial Results
247wallst.com - September 9 at 3:41 AM
marketwatch.com logoKura Oncology's stock rockets after positive results from cancer treatment trial
www.marketwatch.com - September 9 at 3:41 AM
reuters.com logoBRIEF-‍Great Point Partners LLC reports 5.92 percent passive stake in Kura Oncology Inc
www.reuters.com - August 21 at 7:30 PM
streetinsider.com logoKura Oncology (KURA) Prices 7.7M Common Stock Offering at $6.50/Share
www.streetinsider.com - August 12 at 7:22 PM
seekingalpha.com logoKura Oncology's (KURA) CEO Troy Wilson on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 8 at 12:49 AM
reuters.com logoBRIEF-Kura Oncology ‍enters into collaboration agreement with Foundation Medicine
www.reuters.com - July 14 at 6:02 AM
seekingalpha.com logoKura Oncology teams up with Foundation Medicine to support recruitment for tipifarnib clinical trial
seekingalpha.com - July 14 at 6:02 AM
reuters.com logoBRIEF-Kura Oncology Q1 loss per share $0.39
www.reuters.com - May 16 at 10:46 AM
reuters.com logoBRIEF-Kura Oncology doses first patient in phase 1 trial of ERK inhibitor KO-947
www.reuters.com - April 7 at 10:45 AM
zacks.com logoWhy Kura Oncology (KURA) Stock Might be a Great Pick
www.zacks.com - December 8 at 6:47 PM
seekingalpha.com logoKura Oncology's (KURA) CEO Troy Wilson on Q3 2016 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 8:50 AM
reuters.com logoBRIEF-Kura Oncology Q2 net loss $6.7 million
www.reuters.com - August 10 at 6:15 PM
cnbc.com logoKura Oncology reports 2Q loss
www.cnbc.com - August 10 at 6:15 PM
zacks.com logoKura Oncology (KURA) Looks Good: Stock Adds 5.4% in Session
www.zacks.com - July 8 at 8:49 AM
finance.yahoo.com logoKura Oncology Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - November 4 at 6:09 PM

Social

Chart

Kura Oncology (KURO) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff